IN8bio CEO to Present at Sidoti Small-Cap Virtual Conference…

Event summary

IN8bio CEO William Ho to present at Sidoti Small-Cap Virtual Conference on September 24, 2026.
Presentation to cover IN8bio’s γδ T cell platform and pipeline, including lead program INB-619.
One-on-one investor meetings scheduled throughout the conference.
Live webcast available via IN8bio’s Investors section, with replay following the event.

The big picture

IN8bio’s participation in the Sidoti Small-Cap Virtual Conference underscores its focus on engaging with investors to showcase its innovative γδ T cell therapies. The event comes at a critical time for the biopharmaceutical company as it advances its pipeline in oncology and autoimmune diseases, sectors experiencing rapid innovation and high investor interest. The strategic emphasis on T cell engagers and γδ T cell therapies positions IN8bio within a niche but growing segment of the biotech industry.

What we're watching

Pipeline Progress: How IN8bio’s presentation will highlight advancements in its γδ T cell platform, particularly INB-619, and its clinical-stage programs in oncology.
Investor Sentiment: Whether the conference will bolster investor confidence in IN8bio’s differentiated approach to cancer and autoimmune therapies.
Market Positioning: The pace at which IN8bio can differentiate itself in the competitive landscape of T cell therapies.